Anbio Biotechnology share price today

Anbio Biotechnology's share price was $3.68 at the close on 4 November 2026. That is 78.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $37, and at that close it sat 2% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 23 weeks running.

Over the last 1 year the share price moved −93% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 29 May 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Anbio Biotechnology pays no dividend. In the last 8 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Anbio Biotechnology is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Anbio Biotechnology earned $2.6 M of net profit in the Dec 2025 quarter. Full-year FY25 profit was $6.4 M. Over 4 years profit has grown 26.1% a year on average. That is 64.2% of the quarter's revenue. The same quarter a year earlier earned $733 K. 2 of the last 8 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was $6.4 M (+169.8% on the year before).

On average over the last four quarters, profit changed −41.6% and revenue +26.9%. Profit is growing slower than sales: rising costs are taking part of the growth.

Anbio Biotechnology reported $4.1 M of revenue in the Dec 2025 quarter, +73.9% on the same quarter a year earlier. Over 4 years it has grown 18.2% a year on average. The last full year, FY25, came in at $8.6 M.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $8.6 M, +5.6% on the year before.

Recent pace: the last four quarters grew +26.9% on average, against 18.2% a year over the longer run, so this year is growing faster than its own long-run rate.

Anbio Biotechnology's operating margin was 59.1% in the Dec 2025 quarter, 127.7 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Over the last four quarters it has moved +44.3 percentage points. Across 5 years it has been between 24.4% and 66.7%.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

The latest quarter is within that range.

Why the margin moved: operating margin changed +44.3 percentage points on the year while gross margin changed +38.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years Anbio Biotechnology's operations used more cash than they brought in, so cash conversion was −34%, a gap worth watching. In FY25 its operations used $6.7 M of cash, against $6.4 M of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Anbio Biotechnology does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Anbio Biotechnology's P/E is 25.1×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +161.3% while the price moved −78.5%. Earnings did better than the price, which pulled the multiple down within its own range.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Anbio Biotechnology's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Anbio Biotechnology earned a ROE of 21% in FY25. That is up from a low of 14% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads 102%, a number that says nothing useful about the business. It comes from a 74.0% net margin and 0.29× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 74.0% net margin × 0.29× asset turnover × 1.00× leverage (assets divided by equity) ≈ 21.5% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

A history of Anbio Biotechnology's borrowings is not in our data.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

0.1% of Anbio Biotechnology's tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 0.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Anbio Biotechnology, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

There is no score against its industry: Anbio Biotechnology is not among the largest members shown in this industry comparison for Medical Instruments & Supplies.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Anbio Biotechnology is the 38th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: AngioDynamics, Inc., Embecta Corp., Sanara MedTech Inc., OraSure Technologies, Inc., Utah Medical Products, Inc. and Pro-Dex, Inc. It is the smallest.

Medical Instruments & Supplies companies close in size

32. AngioDynamics, Inc. $515 million
33. Embecta Corp. $369 million
34. Sanara MedTech Inc. $297 million
35. OraSure Technologies, Inc. $257 million
36. Utah Medical Products, Inc. $230 million
37. Pro-Dex, Inc. $203 million
38. Anbio Biotechnology $162 million

All 38 Medical Instruments & Supplies companies, largest first

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.